The UK and US have hammered out a important commercial pact that will keep zero import taxes on British pharmaceutical exports being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to raise funding on pharmaceuticals through the public health system. This move ensures that duties on these vital products will remain at nothing for a period of the next three years.
This agreement comes after earlier statements to dramatically increase tariffs on patented pharmaceutical imports, with figures mentioned up to one hundred percent.
"This agreement between the Britain bolsters the international landscape for cutting-edge drugs and brings much-needed fairness to American-British drug exports," an announcement declared.
Commercial Importance
Pharmaceuticals are one of the UK's largest export categories to the US, which is by far the primary buyer for large companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months leading up to the third quarter, the UK sold medicines worth £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that period.
"This agreement safeguards work, boosts capital expenditure and paves the way for the UK to become a worldwide center for life sciences," a minister stated.
Detailed British Pledges
The deal entails several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to raise total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must refund to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates were more than 20%.
Industry Background
This agreement follows a ongoing row between the pharmaceutical industry and the UK government over spending levels and approval rates.
These tensions were exacerbated by claims that American customers were charged a premium for the identical medicines than people in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been delayed or abandoned, while major investments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
